ReviewFrontiers in digital health2025
Digital technologies in psoriasis management: from precision diagnosis to therapeutic innovation and holistic care.
Review in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis, an enduring systemic inflammatory dermatological condition with rising global incidence, presents significant impediments to conventional diagnostic and therapeutic strategies, primarily due to the reliance on subjective evaluation methods, notable adverse effects of treatments, and suboptimal long-term patient adherence. This narrative review systematically explores how digital innovations are transforming its comprehensive management. Digital innovations are transforming its comprehensive management: In diagnosis, artificial intelligence (AI)-integrated dermoscopy (EfficientNet-B4 model) achieves a 92.3% accuracy in differentiating psoriasis from other papulosquamous disorders, surpassing 230 dermatologists (86.7% accuracy) and enhancing severity assessment through deep learning, thereby mitigating subjective bias. In treatment, smart phototherapy devices refine dosage optimization through algorithmic processes, while AI-assisted biologic selection elevates complete clearance rates from 39% to 61% (compared to traditional protocols) with severe adverse events diminishing to less than 2%. In rehabilitation, Internet of things (IoT)-enabled monitoring systems assimilate real-time data through wearable technology and digital platforms to enhance self-management and adaptive intervention strategies. Multi-omics data integration and computational drug design expedite the development of novel therapies. Nevertheless, challenges such as inadequate data standardization, privacy issues, restricted algorithmic transparency, and lack of prolonged validation remain. Digital technologies are reconfiguring psoriasis management from diagnosis (objective imaging) to treatment (personalized dose management) and rehabilitation (IoT-enabled monitoring), establishing a precision-based, data-centric framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.